Follow-up of Pulmonary Radiotoxicity for Bronchopulmonary Cancer. (TEFRARC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03931356|
Recruitment Status : Recruiting
First Posted : April 30, 2019
Last Update Posted : July 18, 2019
|Condition or disease||Intervention/treatment|
|Cancer, Lung Radiotherapy; Complications||Other: Pulmonary function tests|
Radiation therapy with or without chemotherapy is a stable treatment in the management of patients with localized smack cell bronchopulmonary cancers, or not to small cells not metastatic but not operable. Radiation therapy results in changes in respiratory function, as measured by respiratory function tests and represented primarily by spirometry, total body plethysmography, and the diffusion capacity of the alveolar-capillary membrane.
Although these tests are minimally invasive, few studies have investigated the implications of radiation therapy on lung function in patients treated for pulmonary neoplasia, while these patients are often already carriers of respiratory diseases and will receive further chemotherapy during their illness, subject to their general good condition, including respiratory. No method has been recognized as superior for measuring the consequences of radiation therapy on respiratory function. After chest radiotherapy alone, the decline in diffusion capacity is estimated at 10-34%. New irradiation techniques have emerged over the last decade, in particular dynamic arc therapy. This innovative technology, combined with image-guided irradiation processes, ensures high-precision, short-term treatment, but exposes virtually all of the lungs to irradiation, although at very low doses, the objective consequences of which on respiratory functional explorations have never been reported.
The aim of this study is therefore to assess the consequences of low doses of radiation delivered by this recent technology, volumetric therapy, on the respiratory capacity of patients treated with radiotherapy within the framework of of bronchopulmonary carcinoma.
|Study Type :||Observational|
|Estimated Enrollment :||39 participants|
|Official Title:||Follow-up of Pulmonary Toxicity by Respiratory Functional Tests of Patients Treated With Dynamic Cancer ARCtherapy for Bronchopulmonary Cancer.|
|Actual Study Start Date :||January 14, 2019|
|Estimated Primary Completion Date :||January 14, 2021|
|Estimated Study Completion Date :||January 14, 2021|
- Other: Pulmonary function tests
analysis of lung volume and diffusion capacity
- diffusion capacity [ Time Frame: 3 months ]diminution of 20% or more of the diffusion capacity at 3 months
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03931356
|Contact: Ulrike SHICK||02 98 22 33 email@example.com|
|CHRU de Brest (Morvan)||Recruiting|
|Contact: Ulrike SCHICK 02 98 22 33 98 firstname.lastname@example.org|